{"id":60554,"date":"2026-03-23T15:11:58","date_gmt":"2026-03-23T07:11:58","guid":{"rendered":"https:\/\/flcube.com\/?p=60554"},"modified":"2026-03-23T15:11:59","modified_gmt":"2026-03-23T07:11:59","slug":"hengrui-pharmas-her2-adc-shr-a1811-wins-nmpa-approval-for-breast-cancer-second-indication-expands-trastuzumab-rezetecan-franchise","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=60554","title":{"rendered":"Hengrui Pharma&#8217;s HER2 ADC SHR-A1811 Wins NMPA Approval for Breast Cancer \u2013 Second Indication Expands Trastuzumab Rezetecan Franchise"},"content":{"rendered":"\n<p><strong>Jiangsu Hengrui Pharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600276:SHA\">SHA: 600276<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/1276:HKG\">HKG: 1276<\/a>) announced that its <strong>self-developed Category 1 innovative drug, Trastuzumab rezetecan (SHR-A1811)<\/strong>, a <strong>HER2-targeted antibody-drug conjugate (ADC)<\/strong>, has received <strong>NMPA approval<\/strong> for a <strong>new indication<\/strong> in <strong>HER2-positive breast cancer<\/strong> \u2013 marking the <strong>second approved indication<\/strong> for the independently developed ADC and expanding its addressable market beyond the initial <strong>HER2-mutant NSCLC<\/strong> approval.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Trastuzumab rezetecan (SHR-A1811) \u2013 HER2-targeted ADC<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276)<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Category 1 innovative drug (self-developed)<\/td><\/tr><tr><td><strong>New Indication<\/strong><\/td><td>HER2-positive breast cancer (locally advanced or metastatic) \u2013 post-anti-HER2 therapy<\/td><\/tr><tr><td><strong>Prior Approval<\/strong><\/td><td>May 2025 \u2013 HER2-mutant NSCLC (unresectable locally advanced\/metastatic)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-amp-mechanism-of-action\">Product Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Technology:<\/strong> <strong>HER2-targeted antibody-drug conjugate (ADC)<\/strong><\/li>\n\n\n\n<li><strong>Mechanism:<\/strong><\/li>\n<\/ul>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Binding:<\/strong> Trastuzumab component binds to HER2-expressing tumor cells<\/li>\n\n\n\n<li><strong>Endocytosis:<\/strong> ADC-HER2 complex internalized into tumor cells<\/li>\n\n\n\n<li><strong>Payload Release:<\/strong> Cytotoxic payload released in lysosomes via <strong>protease cleavage<\/strong><\/li>\n\n\n\n<li><strong>Cell Death:<\/strong> Induces <strong>cell cycle arrest<\/strong> and triggers <strong>apoptosis<\/strong> (programmed cell death)<\/li>\n<\/ol>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Development Status:<\/strong> <strong>Independently developed by Hengrui Pharma<\/strong> with complete IP rights<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-approved-indications-portfolio\">Approved Indications Portfolio<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Approval Date<\/th><th>Indication<\/th><th>Patient Population<\/th><\/tr><\/thead><tbody><tr><td><strong>May 2025<\/strong><\/td><td>HER2-mutant NSCLC<\/td><td>Unresectable locally advanced or metastatic NSCLC with HER2 (ERBB2) activating mutations; progressed on \u22651 prior systemic therapy<\/td><\/tr><tr><td><strong>March 2026<\/strong><\/td><td><strong>HER2-positive breast cancer<\/strong><\/td><td>Locally advanced or metastatic HER2+ breast cancer; previously received <strong>one or more anti-HER2 therapies<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-strategic-positioning\">Market Context &amp; Strategic Positioning<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Dimension<\/th><th>HER2-Positive Breast Cancer Landscape<\/th><th>SHR-A1811 Position<\/th><\/tr><\/thead><tbody><tr><td><strong>Market Size<\/strong><\/td><td>China ~45,000 new HER2+ breast cancer cases annually; HER2 ADC market RMB6-8 billion<\/td><td>Second approved indication expands addressable market 3-4x vs. NSCLC alone<\/td><\/tr><tr><td><strong>Standard of Care<\/strong><\/td><td>Trastuzumab (Herceptin) \u2192 pertuzumab + trastuzumab \u2192 T-DM1 (Kadcyla) \u2192 T-DXd (Enhertu, DS-8201)<\/td><td>Post-T-DM1\/T-DXd positioning; potential for earlier-line expansion<\/td><\/tr><tr><td><strong>Competitive Dynamics<\/strong><\/td><td>DS-8201 (Daiichi\/AstraZeneca) dominant in post-HER2 therapy setting; domestic biosimilars eroding trastuzumab market<\/td><td>Differentiated payload\/linker vs. T-DXd; potential efficacy\/safety differentiation in head-to-head studies<\/td><\/tr><tr><td><strong>Hengrui ADC Strategy<\/strong><\/td><td>SHR-A1811 lead asset in HER2 ADC franchise; pipeline includes HER2-low, TROP2, CLDN18.2 ADCs<\/td><td>Multi-indication HER2 platform validation supports broader ADC portfolio development<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>HER2 ADC Market Dynamics:<\/strong> Global HER2 ADC market exceeds <strong>US$10 billion<\/strong> annually; China represents <strong>20-25% of volume<\/strong> with DS-8201 (Enhertu) capturing 60%+ share in post-HER2 therapy setting; SHR-A1811&#8217;s second indication positions for <strong>15-20% market share<\/strong> in China HER2+ breast cancer (2027-2030).<\/li>\n\n\n\n<li><strong>Revenue Trajectory:<\/strong> Assuming <strong>RMB800 million-1.2 billion<\/strong> annual peak sales across both indications (2028-2030); breast cancer indication likely 70%+ of volume given larger patient population vs. HER2-mutant NSCLC niche; NRDL inclusion (negotiated 2025-2026) critical for volume scaling.<\/li>\n\n\n\n<li><strong>Clinical Expansion Pipeline:<\/strong> Potential for <strong>earlier-line breast cancer<\/strong> (first-line HER2+ in combination with pertuzumab), <strong>HER2-low breast cancer<\/strong> (following DS-8201 label expansion), and <strong>gastric cancer<\/strong> (HER2+ GC indication under development); global Phase III studies may support ex-China partnerships.<\/li>\n\n\n\n<li><strong>Hengrui Innovation Validation:<\/strong> Second indication approval within 10 months of initial nod demonstrates <strong>regulatory execution capabilities<\/strong> and <strong>clinical data quality<\/strong>; self-developed ADC platform (vs. in-licensing) supports sustainable competitive advantage and margin structure.<\/li>\n\n\n\n<li><strong>Competitive Response:<\/strong> DS-8201&#8217;s efficacy benchmark (DESTINY-Breast03: 75.8% ORR, 25.1 mo PFS) sets high bar; SHR-A1811&#8217;s real-world performance and head-to-head data (if conducted) will determine market share capture vs. premium-priced Enhertu and emerging domestic competitors (RemeGen, ADC Therapeutics China).<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding commercialization expectations, market share projections, and pipeline expansion timelines for SHR-A1811. Actual results may differ due to competitive dynamics with DS-8201, reimbursement negotiations, and clinical performance in real-world settings.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026032001015_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026032001015_c.\"><\/object><a id=\"wp-block-file--media-4f9b8062-b0dc-481f-be1d-979e01cf74a0\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026032001015_c.pdf\">2026032001015_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026032001015_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-4f9b8062-b0dc-481f-be1d-979e01cf74a0\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that its self-developed Category 1&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,16,2586,4228,15,852],"class_list":["post-60554","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-cancer","tag-hengrui-pharmaceuticals","tag-hkg-1276","tag-product-approvals","tag-sha-600276"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hengrui Pharma&#039;s HER2 ADC SHR-A1811 Wins NMPA Approval for Breast Cancer \u2013 Second Indication Expands Trastuzumab Rezetecan Franchise - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that its self-developed Category 1 innovative drug, Trastuzumab rezetecan (SHR-A1811), a HER2-targeted antibody-drug conjugate (ADC), has received NMPA approval for a new indication in HER2-positive breast cancer \u2013 marking the second approved indication for the independently developed ADC and expanding its addressable market beyond the initial HER2-mutant NSCLC approval.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=60554\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hengrui Pharma&#039;s HER2 ADC SHR-A1811 Wins NMPA Approval for Breast Cancer \u2013 Second Indication Expands Trastuzumab Rezetecan Franchise\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that its self-developed Category 1 innovative drug, Trastuzumab rezetecan (SHR-A1811), a HER2-targeted antibody-drug conjugate (ADC), has received NMPA approval for a new indication in HER2-positive breast cancer \u2013 marking the second approved indication for the independently developed ADC and expanding its addressable market beyond the initial HER2-mutant NSCLC approval.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=60554\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-23T07:11:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-23T07:11:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60554#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60554\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hengrui Pharma&#8217;s HER2 ADC SHR-A1811 Wins NMPA Approval for Breast Cancer \u2013 Second Indication Expands Trastuzumab Rezetecan Franchise\",\"datePublished\":\"2026-03-23T07:11:58+00:00\",\"dateModified\":\"2026-03-23T07:11:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60554\"},\"wordCount\":577,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Cancer\",\"Hengrui Pharmaceuticals\",\"HKG: 1276\",\"Product approvals\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=60554#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60554\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=60554\",\"name\":\"Hengrui Pharma's HER2 ADC SHR-A1811 Wins NMPA Approval for Breast Cancer \u2013 Second Indication Expands Trastuzumab Rezetecan Franchise - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-23T07:11:58+00:00\",\"dateModified\":\"2026-03-23T07:11:59+00:00\",\"description\":\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that its self-developed Category 1 innovative drug, Trastuzumab rezetecan (SHR-A1811), a HER2-targeted antibody-drug conjugate (ADC), has received NMPA approval for a new indication in HER2-positive breast cancer \u2013 marking the second approved indication for the independently developed ADC and expanding its addressable market beyond the initial HER2-mutant NSCLC approval.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60554#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=60554\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60554#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hengrui Pharma&#8217;s HER2 ADC SHR-A1811 Wins NMPA Approval for Breast Cancer \u2013 Second Indication Expands Trastuzumab Rezetecan Franchise\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hengrui Pharma's HER2 ADC SHR-A1811 Wins NMPA Approval for Breast Cancer \u2013 Second Indication Expands Trastuzumab Rezetecan Franchise - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that its self-developed Category 1 innovative drug, Trastuzumab rezetecan (SHR-A1811), a HER2-targeted antibody-drug conjugate (ADC), has received NMPA approval for a new indication in HER2-positive breast cancer \u2013 marking the second approved indication for the independently developed ADC and expanding its addressable market beyond the initial HER2-mutant NSCLC approval.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=60554","og_locale":"en_US","og_type":"article","og_title":"Hengrui Pharma's HER2 ADC SHR-A1811 Wins NMPA Approval for Breast Cancer \u2013 Second Indication Expands Trastuzumab Rezetecan Franchise","og_description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that its self-developed Category 1 innovative drug, Trastuzumab rezetecan (SHR-A1811), a HER2-targeted antibody-drug conjugate (ADC), has received NMPA approval for a new indication in HER2-positive breast cancer \u2013 marking the second approved indication for the independently developed ADC and expanding its addressable market beyond the initial HER2-mutant NSCLC approval.","og_url":"https:\/\/flcube.com\/?p=60554","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-23T07:11:58+00:00","article_modified_time":"2026-03-23T07:11:59+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=60554#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=60554"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hengrui Pharma&#8217;s HER2 ADC SHR-A1811 Wins NMPA Approval for Breast Cancer \u2013 Second Indication Expands Trastuzumab Rezetecan Franchise","datePublished":"2026-03-23T07:11:58+00:00","dateModified":"2026-03-23T07:11:59+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=60554"},"wordCount":577,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Cancer","Hengrui Pharmaceuticals","HKG: 1276","Product approvals","SHA: 600276"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=60554#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=60554","url":"https:\/\/flcube.com\/?p=60554","name":"Hengrui Pharma's HER2 ADC SHR-A1811 Wins NMPA Approval for Breast Cancer \u2013 Second Indication Expands Trastuzumab Rezetecan Franchise - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-23T07:11:58+00:00","dateModified":"2026-03-23T07:11:59+00:00","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that its self-developed Category 1 innovative drug, Trastuzumab rezetecan (SHR-A1811), a HER2-targeted antibody-drug conjugate (ADC), has received NMPA approval for a new indication in HER2-positive breast cancer \u2013 marking the second approved indication for the independently developed ADC and expanding its addressable market beyond the initial HER2-mutant NSCLC approval.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=60554#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=60554"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=60554#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hengrui Pharma&#8217;s HER2 ADC SHR-A1811 Wins NMPA Approval for Breast Cancer \u2013 Second Indication Expands Trastuzumab Rezetecan Franchise"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60554","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=60554"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60554\/revisions"}],"predecessor-version":[{"id":60557,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60554\/revisions\/60557"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=60554"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=60554"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=60554"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}